NCT04182581: Phase 1: A Study of BCMA/CD19 Dual-Target CAR-T Cell Immunotherapy for Relapsed Myeloma
- Completed
- Dec 2, 2019
- 1 min read
Updated: Jun 23, 2022
NCT04182581: Phase 1: A Study of BCMA/CD19 Dual-Target CAR-T Cell Immunotherapy for Relapsed or Refractory Multiple Myeloma
A Study of BCMA/CD19 Dual-Target CAR-T Cell Immunotherapy for Relapsed or Refractory Multiple Myeloma
Sponsor:
Xijing Hospital
Gracell Biotechnology Ltd.
The study is an early, open, single-centered trial. The purpose of this study is to evaluate the safety and persistence of BCMA/CD19 dual-target CAR-T cell immunotherapy in relapsed or refractory MM. The study will include 18 subjects to receive BCMA/CD19 dual-target CAR-T therapy.
ClinicalTrials.gov Identifier: NCT04182581
Official Title: A Study of B-cell Maturation Antigen/Cluster of Differentiation Antigen 19 Dual-Target Chimeric Antigen Receptor T Cell Immunotherapy for Relapsed or Refractory Multiple Myeloma
First Posted: December 2, 2019
Click here to see details on ClinicalTrials.gov
Biological: BCMA/CD19 Dual-Target CAR-T
Autologous Bispecific BCMA/CD19-targeted CAR-T Cells GC012F (Code C175471)
Autologous Anti-BCMA/CD19 Dual CAR T Cells GC012F
Autologous Bispecific BCMA/CD19-targeted CAR-T Cells GC012F
Autologous GC012F CAR-T Cells
GC 012F
GC-012F
GC012F
Location
China, Shanxi